Over the past decade, immunotherapy has provided remarkable benefits for cancer patients, and a number of new immune-based approaches that have been developed provide the possibility of relief for many more patients. However, figuring out which immunotherapy strategy will work best for a particular patient remains challenging. That’s where biomarkers, which can shed light on an individual patient’s biology, come in.
With the aid of biomarkers to guide doctors’ decision making, patients can be paired with the treatments most likely to benefit them. In this webinar for patients and caregivers, Kunle Odunsi, M.D., Ph.D., of the Roswell Park Comprehensive Cancer Institute discusses how biomarkers are already being used to help patients today as well as how we’re working to harness the full potential of biomarkers moving forward.
Dr. Odunsi is currently the deputy director, the chair of the Department of Gynecologic Oncology, the M. Steven Piver professor of gynecologic oncology, and the executive director of the Center for Immunotherapy at the Roswell Park Comprehensive Cancer Center, and a professor of gynecology & obstetrics at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo. As a recognized leader in the field of ovarian cancer immunotherapy, Dr. Odunsi has led several clinical trials involving novel immune-based approaches such as vaccines, while his lab focuses on the molecular characterization of tumor antigens in ovarian cancer and refining strategies to target them more effectively.
The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, with additional support from Regeneron, Sanofi Genzyme, and Adaptimmune.
Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series.